• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Oyster point

Quote
anonymous said:
Dear Oyster Point. Thank you for posting a Q4 revenue of six million and paying most of your sales force peanuts. Really wonder how the upper management can feel good about any of this. Oh wait they are all horrible liars and cheats. That’s how.
Click to expand...

are you serious? Clearly you don’t work at OP. If you do you must be one of the bottom feeders who won’t work and wanted it to fall in your lap. Making more money than I ever have but I’m working hard and loving it. Go ahead and move on. We don’t have time for lazy
 




Thanks for the answer upper management. Clarify bottom feeders ??? Is that 90 percent of the sales force ??? I literally know not a single person making bonus at plan right now.
 








anonymous said:
Thanks for the answer upper management. Clarify bottom feeders ??? Is that 90 percent of the sales force ??? I literally know not a single person making bonus at plan right now.
Click to expand...


Hahahahaha. I think they did answer you. You may want to go back and read their original post. They very clearly told you how you’re a bottom feeder. Don’t worry - everybody reading this knows you suck. Go ahead and head back to McDonalds where you belong. Hahahahahaha
 








They need to revisit the car situation Target of 800 a month?? Only if you drive a ton. Drive a ton, pay for more gas and at these prices means less money in your pocket to pay for your car and insurance and maintenance.
 




anonymous said:
They need to revisit the car situation Target of 800 a month?? Only if you drive a ton. Drive a ton, pay for more gas and at these prices means less money in your pocket to pay for your car and insurance and maintenance.
Click to expand...

my problem is less about the car issues and more about the $8 stock price and broad low uptake Tyrvaya. I’m not expecting to get rich on the car plan but the stock price and sales are what will allow us to continue to operate and propel our company into the future
 




Yes, Low uptake of Tyrvaya RX’s is a reality. However, when taken into context that we are outperforming recent previous dry eye competitors launch trajectories (and they didn’t launch in a pandemic with access issues), the uptake rate which is better than theirs is actually exceptional for this therapeutic space. The real problem comes when the company hasn't figured out how to be competitive in IC payout during a launch. Even with all the adjustments to date it still remains non competitive with even against mediocre launches of other products. When more the majority of the company makes less than 5k in a early launch quarter and they are outpacing previous dry eye production launches from competitors, thats a problem. Most of these reps made that kind of money in Quarterly IC in non launch scenarios at other companies before taking this job. In a normal competitive IC launch especially when you are outpacing previous competitor launches, you are pulling in 15-40k in the first couple quarters. Good product, good early IC strategy on breadth, really poor IC payout even after adjustments.
 




anonymous said:
Yes, Low uptake of Tyrvaya RX’s is a reality. However, when taken into context that we are outperforming recent previous dry eye competitors launch trajectories (and they didn’t launch in a pandemic with access issues), the uptake rate which is better than theirs is actually exceptional for this therapeutic space. The real problem comes when the company hasn't figured out how to be competitive in IC payout during a launch. Even with all the adjustments to date it still remains non competitive with even against mediocre launches of other products. When more the majority of the company makes less than 5k in a early launch quarter and they are outpacing previous dry eye production launches from competitors, thats a problem. Most of these reps made that kind of money in Quarterly IC in non launch scenarios at other companies before taking this job. In a normal competitive IC launch especially when you are outpacing previous competitor launches, you are pulling in 15-40k in the first couple quarters. Good product, good early IC strategy on breadth, really poor IC payout even after adjustments.
Click to expand...

I agree with most of your post. Can’t relate to the IC part. I made over 20k in 2 months of launch last year and on track to do more this quarter. Most of my district is similar.
 




anonymous said:
Yes, Low uptake of Tyrvaya RX’s is a reality. However, when taken into context that we are outperforming recent previous dry eye competitors launch trajectories (and they didn’t launch in a pandemic with access issues), the uptake rate which is better than theirs is actually exceptional for this therapeutic space. The real problem comes when the company hasn't figured out how to be competitive in IC payout during a launch. Even with all the adjustments to date it still remains non competitive with even against mediocre launches of other products. When more the majority of the company makes less than 5k in a early launch quarter and they are outpacing previous dry eye production launches from competitors, thats a problem. Most of these reps made that kind of money in Quarterly IC in non launch scenarios at other companies before taking this job. In a normal competitive IC launch especially when you are outpacing previous competitor launches, you are pulling in 15-40k in the first couple quarters. Good product, good early IC strategy on breadth, really poor IC payout even after adjustments.
Click to expand...

I feel we will be treated fairly from an IC standpoint. I believe that. It is however hard to compare our launch to these recent launches spoken of an get any real comfort from that. Me too drugs are not supposed to be block busters. This stock price is a concern and uptake. Sure we have isolated places where $20k was achieved but it wasn’t the norm. Don’t want to argue but just my feelings.
 




anonymous said:
They need to revisit the car situation Target of 800 a month?? Only if you drive a ton. Drive a ton, pay for more gas and at these prices means less money in your pocket to pay for your car and insurance and maintenance.
Click to expand...
I am paying over $20 per day for gas and it’s getting worse. I am loosing so much on this car it’s insane.
 




anonymous said:
I am paying over $20 per day for gas and it’s getting worse. I am loosing so much on this car it’s insane.
Click to expand...

And your getting reimbursed for it, you’re just too dumb to understand. People that are complaining belong in Big pharma. If you’re not making IC it’s because you’re not closing. The IC plan is attainable, just need to hustle, which clearly lacking in some areas.
 




anonymous said:
And your getting reimbursed for it, you’re just too dumb to understand. People that are complaining belong in Big pharma. If you’re not making IC it’s because you’re not closing. The IC plan is attainable, just need to hustle, which clearly lacking in some areas.
Click to expand...

please keep this a space of civil dialogue. Calling others too dumb is not helping. Slow uptake will in turn continue to cause the stock price to drop or stay stagnant. Having a few performers will not make up for this. As for the car it isn’t ideal but that is the risk we took. This should be a forum for solutions and encouragement. We don’t want to start losing people. Let’s turn this around.
 




How OP hired the sales force and what was selective will have to be re evaluated. Its OK to have the desire of a 50/50 split but some hired 20 + years who were non performers at other companies. Those managers are relying on those tenured reps so who is leading who? No eye care isnt always ideal but with that you need more time. The sales calls from them are all data and no scenario or real world discussion. I feel we have both of those spectrums and nothing in the middle. Accountability is everywhere for leadership choices of some hires to execution. We can power forward but it will take extra hustle and taking ownership of learning the space to be more effective in the field. For the super tenured eye care people who arent leading the pack, they should be put on a PIP. They sold in the interview how good they are and "who they know? and they haven't put up.
 




anonymous said:
How OP hired the sales force and what was selective will have to be re evaluated. Its OK to have the desire of a 50/50 split but some hired 20 + years who were non performers at other companies. Those managers are relying on those tenured reps so who is leading who? No eye care isnt always ideal but with that you need more time. The sales calls from them are all data and no scenario or real world discussion. I feel we have both of those spectrums and nothing in the middle. Accountability is everywhere for leadership choices of some hires to execution. We can power forward but it will take extra hustle and taking ownership of learning the space to be more effective in the field. For the super tenured eye care people who arent leading the pack, they should be put on a PIP. They sold in the interview how good they are and "who they know? and they haven't put up.
Click to expand...

This is well thought out except for the PIP part. It’s a little early to start talking like that. This is going to take time and everyone should be treated the same or reps will leave and set us farther behind.
 




I’ll have to admit that I have not done so well. My Buddy has done extremely well but he is not the norm. This is happening slow in places and even slowing down. Not a good feeling.
 








At least we have Jeff Nau. I literally prayed that John Snisarenko would retire when I was at church today. Now two doctors said the same after meeting him in New Orleans. They said they would say whatever they assumed he ensued to hear just ti get the F out of the interaction. PLEASE disacciaye with John Sniz for the sake of customers and field personnel. He is awkward and unnecessary. Your investors will thank you.
 








anonymous said:
Agree
Incompetent JS who Takeda didn’t want, Novartis didn’t want so he’s at some dry eye start up hoping to sell out while selling the kool aid and once again lying to the commercial team
Liar
Loser
Cheater
Alcoholic
Weirdo
Click to expand...

unfortunately,they’re right about Aniz. He’s a liability, old, brings nothing other than “remember when in retina….?”….

get a life JS
 




Top Bottom
Back
Quote